文献速递毛发、甲与色素性疾病

外用他克莫司预防不稳定肢端白癜风新发皮损的随机前瞻研究

A randomized prospective study to assess the role of topical tacrolimus as preventive therapy in unstable acral vitiligo.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-08-07

这项单中心随机前瞻研究纳入60例16-60岁对称性不稳定肢端白癜风患者,1:1分组比较0.1%他克莫司软膏涂抹白斑及正常皮肤(A组)与仅涂抹白斑(B组)6个月的效果。A组皮损数量减少5.6% vs B组2.3%(p=0.001),脱色面积减少10.5% vs B组4.6%(p=0.048)。结论认为涂抹白斑及周围皮肤可有效预防新发皮损并加速复色。

要点

  • A组皮损数量减少5.6%,B组减少2.3%(p=0.001)。
  • A组脱色面积减少10.5%,B组减少4.6%(p=0.048)。
  • 60例中11例(18.3%)治疗失败。

核心结论

  • 0.1%他克莫司软膏涂抹白斑及白斑周围皮肤可有效预防不稳定肢端白癜风新发皮损并加速复色。

研究设计与样本

  • 单中心随机前瞻研究,纳入60例16-60岁对称性不稳定肢端白癜风患者,1:1随机分组,观察6个月,仅评估手腕关节以远的远端手部。

主要发现

  • A组皮损数量减少5.6% vs B组2.3%(p=0.001)。
  • A组脱色面积减少10.5% vs B组4.6%(p=0.048)。
  • 60例中11例(18.3%)治疗失败。

关键数值与推荐

  • A组:0.1%他克莫司软膏涂抹白斑及正常皮肤,每日用药(原文未明确频次),疗程6个月。
  • B组:0.1%他克莫司软膏仅涂抹白斑皮肤,疗程6个月。
  • 每月评估皮损数量、总面积、原有皮损扩展及不良反应。

临床怎么用

  • 对于不稳定肢端白癜风,可考虑将0.1%他克莫司软膏涂抹于白斑及周围正常皮肤以预防新发皮损并促进复色。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acral vitiligo is a significantly distressing condition and tends to be treatment-resistant. The occurrence of new lesions on acral areas further causes greater psychological trauma. Topical tacrolimus has been widely used in the management of vitiligo and its role in preventing flares in other dermatoses such as atopic dermatitis has been well documented. OBJECTIVES: To assess the role of topical tacrolimus as preventive therapy in unstable acral vitiligo. MATERIALS AND METHODS: In this single-centre randomized prospective study, 60 patients aged 16-60 years having unstable acral vitiligo with symmetrical lesions were enrolled and randomized (1:1) into two groups. Patients in group A were instructed to apply topical tacrolimus 0.1% ointment on both vitiliginous and normal skin while patients in group B were instructed to apply topical tacrolimus 0.1% ointment only on vitiliginous skin for 6 months. Only the distal hand till the wrist joint was chosen for observation. Vitiliginous patches were assessed monthly for 6 months for a change in the number of lesions and total area involved, extension of preexisting lesions and adverse effects if any. RESULTS: A reduction in the number of lesions was observed in both groups. The decrease in the number of lesions in group A was 5.6% as compared to 2.3% in group B (p-0.001). The decrease in depigmented area in group A was 10.5% as compared to 4.6% in group B (p-0.048). Treatment failure was seen in 11 out of 60 (18.3%) patients. CONCLUSION: Tacrolimus 0.1% ointment application showed effectiveness in preventing the appearance of new lesions in unstable acral vitiligo and hastening the repigmentation when applied on both lesional and perilesional skin in vitiligo.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Kumar D, Thakur V, Subburaj K, et al. A randomized prospective study to assess the role of topical tacrolimus as preventive therapy in unstable acral vitiligo. J Eur Acad Dermatol Venereol. 2023. PMID: 37467136. doi:10.1111/jdv.19362

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。